Investment
Features
FeesSafety
Academy
More
Pluang+

Maple Finance doubles SYRUP token buyback in September as revenue allocation rises to 20%.

Protocol Fundamentals
19 Oct 2026
Tokenpost
View Source
Bullish
Maple Finance doubles SYRUP token buyback in September as revenue allocation rises to 20%.

Maple Finance increased its SYRUP token buyback in September, purchasing 1,371,166 tokens for $314,116, doubling the amount bought in August. This rise was due to the buyback allocation increasing from 10% in August to 20% in September, based on protocol revenue. The company’s loan balance fell 9% to $1.67 billion by the end of Q3, while quarterly revenue remained steady at $4.4 million. The buybacks are part of MIP-021, which ties token purchases directly to monthly protocol revenue, treating them as a use of revenue rather than dividends.

Maple Finance's SYRUP token buyback doubled in September to 1,371,166 tokens worth $314,116, based on increased protocol revenue allocation. For readers following the broader cryptocurrency market, here is Pluang's snapshot as of Oct 20, 2026 04:42 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell. Notable movers include BAT at Rp3.544 with a 15.27% increase and a near-even Pluang order split, CRV at Rp6.603 down 11.35% with 99% sell activity, and BAL at Rp16.297 up 11.14%, with typical hold times ranging from 62 to 93 days on Pluang.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App